Stock NVCT NUVECTIS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Nuvectis Pharma, Inc.

Equities

NVCT

US67080T1088

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-26 EDT 		5-day change 1st Jan Change
6.5 USD -8.45% Intraday chart for Nuvectis Pharma, Inc. +0.78% -22.06%
05-07 Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-08 Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Precision Medicine M&A is Transforming the Future of the Biotech Industry
AQ
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
GL
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
AQ
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
GL
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
AQ
Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
CI
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
GL
Nuvectis Pharma to Present at the 36th Annual Roth Conference
GL
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
GL
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
AQ
Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer
CI
Nuvectis Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
AQ
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
GL
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
AQ
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
GL
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NVCT Stock
  4. News Nuvectis Pharma, Inc.